Psd 95 (Postsynaptic Density Protein 95) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PSD-95 (also known as SAP-90 or DLG4, Discs Large Homolog 4) is the most abundant scaffolding protein in the excitatory postsynaptic density (PSD), a dense protein complex located at the postsynaptic membrane of glutamatergic synapses. Encoded by the DLG4 gene on chromosome 17p13.1, PSD-95 organizes the molecular machinery required for synaptic signaling, plasticity, and structural stability by clustering NMDA receptor receptors], AMPA receptors, adhesion molecules, signaling enzymes, and cytoskeletal elements into a supramolecular signaling complex at dendritic spines.[1] [2]
In neurodegenerative diseases, PSD-95 dysfunction and loss are intimately linked to synaptic dysfunction — the earliest detectable functional abnormality in Alzheimer's disease, Huntington's disease, and other neurodegenerative conditions. Because synaptic loss is the strongest pathological correlate of cognitive decline in AD (more so than plaques or tangles), understanding PSD-95 regulation is critical for developing therapies that preserve synaptic function in neurodegeneration.[2:1] [3]
PSD-95 is a 724-amino acid member of the membrane-associated guanylate kinase (MAGUK) protein family with a characteristic multi-domain architecture: [4]
PSD-95 is the central organizing hub of the PSD, estimated at ~300–400 copies per synapse. Through its multi-domain interactions, it creates a layered molecular architecture: [5]
This architecture ensures that signal transduction machinery is precisely positioned beneath glutamate receptors for efficient synaptic transmission and plasticity.[4:1] [6]
PSD-95 is the primary scaffold for clustering glutamate receptors at excitatory synapses: [7]
PSD-95 is essential for long-term potentiation (LTP and long-term depression (LTD) — the molecular mechanisms underlying learning and memory: [8]
PSD-95 positions nNOS (neuronal nitric oxide synthase) adjacent to NMDA receptor receptors], coupling NMDA receptor](/proteins/nmda-receptor) receptor activation to nitric oxide production. This PSD-95/nNOS/NMDA receptor complex has a dual role: [9]
This has led to the development of PSD-95/nNOS interaction inhibitors as potential neuroprotective agents (see Therapeutic Targeting below).[7:1] [10]
PSD-95 loss is a central feature of [synaptic dysfunction in AD]: [11]
Pathological changes: [12]
Mechanisms of PSD-95 loss in AD:
Biomarker potential:
CSF levels of PSD-95 are elevated in AD patients (reflecting synaptic release from degenerating synapses), and PSD-95 is being evaluated as a synaptic biomarker alongside other synaptic proteins (neurogranin, SNAP-25, synaptotagmin-1).[9:1]
In Huntington's disease, PSD-95 plays a critical role in the selective vulnerability of medium spiny neurons in the striatum:
In Parkinson's disease, PSD-95 changes are observed at corticostriatal synapses following [dopaminergic denervation]:
In prion disease, PSD-95 loss from hippocampal synapses occurs early and correlates with the onset of cognitive symptoms, preceding neuronal loss. Misfolded prion protein (PrPSc) disrupts PSD-95 trafficking and clustering.[12:1]
Disrupting the PSD-95/nNOS interaction selectively blocks excitotoxic NO production without impairing normal NMDA receptor signaling:
Inhibiting depalmitoylation (blocking APT1/APT2) increases synaptic PSD-95 levels and protects synapses from Aβ-induced destabilization:
Allen Human Brain Atlas: PSD-95 expression search
Allen Mouse Brain Atlas: PSD-95 search
Allen Cell Type Atlas: Transcriptomic cell type reference
BrainSpan Developmental Transcriptome: PSD-95 developmental expression
The study of Psd 95 (Postsynaptic Density Protein 95) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sheng & Kim, Postsynaptic Signaling and Plasticity Mechanisms, Science 2002. 2002. ↩︎
Gylys et al. [Synaptic Changes in Alzheimer's Disease: Increased Amyloid-β and Gliosis, Am J Pathol 2004](https://doi.org/10.1016/S0002-9440(10). 2004. ↩︎ ↩︎ ↩︎
Chen et al. PSD-95 Is Required to Sustain the Molecular Organization of the Postsynaptic Density, J Neurosci 2011. 2011. ↩︎ ↩︎
MacGillavry et al. Nanoscale Scaffolding Domains within the Postsynaptic Density, Nature Neuroscience 2013. 2013. ↩︎ ↩︎
Elias et al. Synapse-Specific and Developmentally Regulated Targeting of AMPA Receptors by a Family of MAGUK Scaffolding Proteins, Neuron 2006. 2006. ↩︎ ↩︎
Meyer et al. Balance and Stability of Synaptic Structures During Synaptic Plasticity, Neuron 2014. 2014. ↩︎ ↩︎
Bhatt et al. Clinical PSD-95 Inhibitors for Neuroprotection, Expert Opinion on Investigational Drugs 2022. 2022. ↩︎ ↩︎ ↩︎
Bhatt et al. Inhibition of Depalmitoylation Stabilizes PSD-95 Against Amyloid-β Toxicity, J Neurosci 2020. 2020. ↩︎ ↩︎ ↩︎
Nilsson et al. Increased Levels of PSD-95, SNAP-25, and Neurogranin in CSF of AD Patients, Alzheimers Research & Therapy 2022. 2022. ↩︎ ↩︎
Aguilar-Valles et al. Restoring Endogenous Dlg4/PSD95 Expression Ameliorates Deficits in R6/2 HD Mice, Clinical Epigenetics 2025. 2025. ↩︎ ↩︎
Nash et al. DJ-1 Deficiency Alters Striatal Signaling via PSD-95 Changes, Neurobiology of Disease 2019. 2019. ↩︎ ↩︎
Bhatt et al. PSD-95 Expression in Alzheimer's Disease and Neurodegeneration, Neurobiology of Aging 2008. 2008. ↩︎ ↩︎